NG Billy Wai-Lung 吳濰龍

Dr. Ng Billy Wai-Lung

  • Assistant Professor, School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong

Professor Ng’s research interests are chemical biology, drug discovery, and medicinal chemistry. The Ng lab (School of Pharmacy, the Chinese University of Hong Kong) uses chemical and biological tools to develop novel small molecules for the treatment of various diseases, including cancers, infectious and neurodegenerative diseases. He has co-authored more than 30 papers in prestigious journals such as Science, Nature Chemical Biology, Molecular Cell, J. Am. Chem. Soc., Angew. Chem. Int. Ed., and ACS Central Science and also serves as a reviewer for more than 30 journals including Science Translational Medicine, Nature Chemical Biology, and Nature Communications.

Professor Ng obtained his B.Sc. degree in Chemistry (1st Class Hons.) and Ph.D. in Organic Chemistry from the Chinese University of Hong Kong. During his graduate study, he was a Fulbright Scholar at Massachusetts Institute of Technology (MIT), under the generous funding supports from the Lee Hysan Foundation and the Fulbright Program. From 2014 – 2016, he joined the University of Oxford as a Croucher Foundation Postdoctoral Fellow. He was then recruited to Harvard Medical School / Dana-Farber Cancer Institute as a research fellow from 2016 – 2019. He was honored as a Young Global Leader (2022) by the World Economic Forum. His research has been funded by diverse sources, including the Bill & Melinda Gates Foundation, US National Academy of Medicine (NAM), the Innovation and Technology Fund (ITF), and Research Grants Council (RGC) of Hong Kong.

ZHU YeQing

Mr. Zhu YeQing

  • Chairman of the Board and CEO, New Horizon HealthCouncil Member, China Cancer FoundationHonorary Vice Chairman, Zhejiang Provincial Bridge Association

Co-founder of New Horizon Health (6606.HK), Mr. Zhu is the Chairman of the Board and CEO of New Horizon Health, transforming the organization into one of the most recognized bio-tech companies in China. In Feb. 2021, New Horizon Health became the first Chinese cancer screening company successfully listed on the main board of HK Exchange.

Mr. Zhu led New Horizon Health through the development, clinical trail, regulatory approval, and commercialization of Pupu tube ®, ColoClear ® and UU tube ®. ColoClear® is the first and only cancer screening test received NMPA approval as well as the first and only colorectal cancer screening test recommended by China national colorectal cancer prevention and diagnostic guidelines. UU Tube® is the first NMPA-approved consumer self-testing product for H.Pylori and Pupu Tube® is the first NMPA-approved consumer self-testing product for FIT (fecal immunochemical test), a screening test for colon cancer.

Before joining New Horizon Health, Mr. Zhu served as the Managing Director of GE Capital Asia and held multiple leadership positions in GE China and Samsung C&T.

Mr. Zhu holds a Bachelor of Science degree in biology and earned his MBA degree both from Beijing University.

HU Hong-Ming, 胡红明

Hu Hong-Ming, PhD

  • Immuxell, Founder, Chairman, and CSO
    Shanghai China

Education Ph.D. in Tumor Immunology, Oregon Health and Science University, Port-land, Oregon, 2002.

M.S. in Molecular Biology, Shanghai Institute of Biochemistry,
Chinese Academy of Science, Shanghai, China, 1990.

B.S. in Biochemistry, School of Life Science,
Fudan University, Shanghai, China, 1987.

Professional Experience
Employment
Lab Chief, Laboratory of Cancer Immunobiology,
Earle A. Chiles Research Institute, Providence Medical Center, Portland, Oregon. 2003-2020.

Senior Research Associate, Laboratory of Dr. Bernard A. Fox
Earle A. Chiles Research Institute, Providence Medical Center,
Portland, Oregon. 1994-2003.

Research Associate, Laboratory of Dr. Vishva M. Dixit,
Department of Pathology, University of Michigan Medical School,
Ann Arbor, Michigan. 1991-1994.

Affiliations
ImmuXell, Founder, Chairman, and CSO 2021-
UbiVAC, CSO 2010-

Clinical adjunct professor, Department of Radiation Oncology,
Oregon Health and Science University (OHSU), Portland, Oregon.
2006-2013.

Adjunct Professor, Department of Physics,
Portland State University, Portland, Oregon. 2009-2014.

Guest Professor, School of Medicine, Xian Jiaotong University 2004-2008
Guest Professor, Shanghai Jiaotong University 2018 to 2020

Honor and Awards

American Cancer Society Research Scholar (2003-2007)

TSUR, Avi

Dr. Avi Tsur

  • Deputy Chief Transformation Officer, Director of The Women’s Health Innovation Center, Director of OBGYN Beyond, Chief Medical Officer Sheba

• Founder and Director of the Sheba Women’s Health Innovation Center: A collaborative effort of ARC, the Sheba Department of Obstetrics & Gynecology and the Gertner Institute for Health Policy and Epidemiology.

• Director of Obstetrics & Gynecology Beyond Department: The first virtual Obstetrics and Gynecology Department providing cutting edge remote women’s healthcare services within Israel and Beyond (part of Sheba Beyond Virtual Hospital).

• Deputy Chief Transformation Officer – The Sheba Medical Center

• Attending Physician: Obstetrics and Gynecology Antepartum (high-risk pregnancy) Department and High-risk Pregnancy Clinics (Sheba).

• Track record of high impact publications: Author of 59 peer reviewed manuscripts and three book chapters (https://publons.com/researcher/AAJ-8372-2021/)

• Principal Investigator of two prospective studies investigating comprehensive remote care at home for women with gestational diabetes and women reaching post-date pregnancy, and an additional study investigating ongoing non-invasive fetal monitoring.

• Industry:
o Inventor of two patents.
o Co-Founder and CMO of SHELA (Maternal-Fetal Precision Medicine)
o Co-Founder of Pregnantech (Developing the Lioness for prevention of preterm birth).
o CMO of Signalife Ltd (Innovative method for measuring fetal saturation during labor and delivery)
o Advisor of Pollie Ltd (Developing virtual programs for PCOS).
o Member of LionBird VC Rings.

Education and Training:
• MD from the Hebrew University (2012).
• OBGYN Residency at The Sheba Medical Center (2012-2016)
• Additoinal Clinical and Scientific Training as Visiting Fellow at The Stanford University Medical Center and March of Dimes Prematurity Research Center (2016-2019)

JUAN-OTERO, Manel

Dr. Manel Juan-Otero

  • Head of Immunology, Hospital Clínic de Barcelona

Degree and Doctorate: Medicine and Surgery (1988 and 1994)
Clinical specialty: Immunology (1994)
1) CLINICAL WORK:
Head of Immunology Service / department (2020 -).
Direct Responsabilities; – Cell immunotherapy + Cytometry coordination + 3 main approaches: DCs + TILs + CART . 1 approved product (ARI0001, CART19, Hospital Exemption)
2) TEACHING:
Assistant Professor (2015 -). Medical School, Universitat de Barcelona (UB).
Assistant Professor of Immunology (1997- 2007). Medical School. UAB.
Coordinator in master of autoimmune diseases (UB); 10 directed doctoral theses (5 co-directed)

3) RESEARCH (SUMMARY):
165 originals, more than 25 reviews and 6 books as publisher
162 articles in journals with IF (15 national and 147 international);
Total IF: 705.060
Publications in last 2.5 years: 44 articles since 2020
Communications: 91 National + 138 International Congresses.

5 active projects + 12 previous projects projects as Principal Investigator + 17 projects as a research collaborator. 6 patents (4 PCT).

BIOHK 2023 Student Ambassador Program Information Sheet

What is BIOHK2023?

BIOHK, or Hong Kong International Biotechnology Convention, is an annual international convention organized by the Hong Kong Biotechnology Organization (HKBIO) to introduce novel state-of-the-art biotech innovations from around the globe, with the purpose of providing an extensive platform to allow pioneers of the biotech industry to convene (e.g., scholars, investors, entrepreneurs). This year, BIOHK will be held from 13-16 September 2023 at Hong Kong Convention & Exhibition Center, with the theme of Biotech Kaleidoscope. From infectious diseases like COVID-19 to the latest cancer treatments and diagnostics to big data analytics, BIOHK2023 hopes to cover the most relevant and timely topics in biotechnology. For the latest information on the event, please visit https://2023.bio-hk.com/

BIOHK2023 Student Ambassador Program

This year, BIOHK launches the BIOHK Student Ambassador Program, for talents in Hong Kong who are passionate about biotechnology and aspire to make a positive impact on the industry to participate as student ambassadors. The benefits and outcomes, duties and responsibilities, and application procedures are listed below.

  1. Objectives

We aim to support the personal and career development of local biotech talents through learning about the latest biotech development and industry landscape, networking with potential supervisors, and gaining experience in a conference organization.

2. Benefits and Outcomes

As a BIOHK Student Ambassador, you will earn the following:

  • Networking opportunities with industry leaders and experts
  • Complimentary registration and priority access to BIOHK 2023
  • Certificate of contribution
  • Payment (the exact amount will depend on the level of contribution).
  • Awards will be given to the best ambassador in each team.

3. Duties and Responsibilities

The program will begin from June 2023 (once the application is approved) to 16th September 2023 (the end of the convention).

According to the order of interest in the application form, successful applicants will be allocated to one of the four teams. They are the Event planning team, Promotion team, Publication team, and Event helper team.

Examples of tasks:

  • Event Planning Team: proposal of the guest list
  • Promotion Team: social media, pamphlet design
  • Publication Team: online article, program notes
  • Even Helper Team: answering and redirecting emails, registration, photo taking

Within each team, there should be at least one full-time helper (team head), who will be paid monthly and will be responsible for weekly meetings with other team heads, task design, and communication with student ambassadors. Meanwhile, part-time ambassadors will help with the tasks assigned by the team head, attend the convention and share the convention within their social network. Payment will be given based on contribution.

4. Eligibility

All undergraduate students or graduates of science, engineering, computer science, or business–related degrees in Hong Kong are eligible for application.

5. Application

Please submit the application form via https://forms.gle/cTEcToKRZebC4tuA6 by 24th June 2023 (Saturday). Any late submission will not be accepted. Applicants will then be selected by their academic results, biotech-related experience, career plan, and strengths/ skills. Supporting documents may include a personal photo, curriculum vitae, transcript, letter of recommendation, etc. In case of an overwhelming number of applicants, interviews will be arranged (details to be announced).

Contact information

Program Director: Bobo Hung biohk.ap@gmail.com.

我的事務所-3月3日-訪問于常海教授:3D金屬打印與生物科技,特別嘉賓:丘榮豐先生

金屬足踝骨 圖片來源:https://startupbeat.hkej.com/?p=77307

今次新城財經台的劉婉芬女士繼續和香港生物科技協會主席于常海教授和科能(Koln 3D)創辦人及行政總裁丘榮豐先生。一起探討如何利用3D金屬打印,幫助殘疾人士重新活動。于教授和丘先生的訪問由07:43 分開始。

相關節目重溫,可瀏覽新城財經台網頁︰https://www.metroradio.com.hk/MetroFinance/Multimedia/wmpopup_archive2.asp?https://arch.metroradio.hk/104/20230303/104_202303032030.mp3